Infection of NMRI mice with increasing doses of six different strains of herpes simplex virus type 1 (HSV-1) induced increasing levels of neutralizing antibodies. In contrast, three strains of HSV-2, irrespective of the dose, induced only marginal antibody responses. Only strain HG 52 (HSV-2) at high doses of infection stimulated antibody formation. The virus content of some organs in 6-to 8-week-old mice appeared to be lower after HSV-2 than after HSV-1 infection. Application of immunemodulating drugs [silica or poly(I).poly(C) coupled via L-lysine to CM-cellulose] resulted in little augmentation of antibody formation if compared to HSV-1 infection. Secondary infections with HSV-1 or HSV-2 after a primary dose of HSV-1 were followed by a marked booster response. In contrast, a primary infection with HSV-2 suppressed secondary responses of HSV-I and HSV-2, thus indicating fundamental differences between the antibody-stimulating potency of HSV-1 and HSV-2 strains.
INTRODUCTION
In vivo models of herpes simplex virus (HSV) infections in mice are generally concerned with spread of virus and localization of its constituents, the state of the latent virus genome and its reactivation. Besides these, studies on host resistance or cellular immunity have been performed. However, in the field of humoral immunity many problems still remain unresolved. Despite this fact, far-reaching conclusions have been drawn from the correlation between the extent of humoral antibody response against HSV-2 and the incidence of cervical cancer in females (Rawls et al., 1968) . The positive correlation between elevated antibody titres and appearance of neoplasia has stimulated extensive investigations. Moreover, in general, the level of humoral antibodies is taken as the main determinant of immunity and successful immunization. It has to be considered, however, that such correlations, between the extent of antibody formation and the incidence of cervical cancer, depend on the assumption that increasing amounts of HSV antigen will stimulate the production of higher antibody levels.
In previous investigations we have studied the influence of host genetics and hormonal factors on the HSV-l-induced antibody response in mice (Knoblich et al., 1983a) and have performed studies on generation and enhancement of antibody formation . In this context, we investigated the divergent interactions of different types and strains of HSV with macrophages (G6ertz et aL, 1984) . In order to analyse better the mechanism of HSV-induced antibody formation, further information is required on the influence of HSV components on antibody formation. The present study describes the ability of various strains of HSV-1 and HSV-2 to induce antibody formation in mice and rats. P. KAMPE AND OTHERS to keep the pH at about 7.2. Viruses were grown either on Vero or on BHK-21 cells. We used HSV-I strains Lennette (G6ertz et al., 1984) , 17 syn ÷ (Brown et al., 1973) , A N G (Schr6der et al., 1981) , AN G path (Kaerner et al., 1983) , WAL (Schr6der et al., 1981) , KOS (G6ertz et al., 1984) and the HSV-2 strains D-316 (G6ertz et al., 1984 ), HG 52 (Halliburton & Timbury, 1976 , Lux syn 292/74 (Bfirfent, 1979) and BRY, which is thymidine kinasenegative (Thouless, 1972) .
Titration of organs Jor virus content. Organs frozen at -70 °C were thawed and specimens were serially diluted 10-fold after disruption of cells with a Branson Sonifier (Knoblich et al., 1983a) . Portions (0.2 ml) of each dilution were added to roller tubes containing Vero cell monolayers. Cultures were examined over the following 6 days for cytopathic effects.
Virus titres were calculated as the average of the log10 of the highest dilution producing a cytopathic effect. Neutralization test. Titres of neutralizing antibodies were determined by a 50~ endpoint method as described earlier (Knoblich et al., 1983b) . Briefly, appropriate volumes of diluted sera were mixed with 30 to 50 p.f.u, of a virus suspension. After incubation for 1 h at 37 °C, samples of this mixture were pipetted onto cell monolayers in stationary roller tubes. Virus that had not been neutralized by antibodies was allowed to adsorb. Two h later, diluted human serum with a high anti-HSV activity (complement fixation titre 1 : 64) was added. Plaques were counted 2 days later and the titres were calculated in relation to the virus control.
The results are expressed as average values +_ standard deviations. Statistical evaluation was done by Student's t-test (P<0.05).
EL1SA. Flat-bonom microtitre plates (96-well, Nunc) were coated with NP40-solubilized antigen at 1 gg protein per well. Antigens were prepared from mock-infected and HSV-infected BHK-21 cells. Coating was performed overnight at 4 °C. Any remaining binding sites of the plastic surface were blocked by incubation with 0.4% gelatine (Serva, Heidelberg, F.R.G.) in phosphate-buffered saline pH 7.4 containing 0-05 % Tween 20 (PBSTween 20). Sera to be tested were diluted with PBS-Tween 20 and added to the microwells. Each serum dilution was tested for binding with control and HSV antigen. Serum dilutions were incubated for 1 h at 37 °C. Then 25 gl of diluted (1:1000) rabbit anti-mouse IgG-alkaline phosphatase conjugate (Sigma) was added. Plates were incubated for 1 h at 37 °C. Washing steps were included where necessary. The binding of antibody was visualized by addition of p-nitrophenylphosphate (1 gg/ml in diethanolamine buffer pH 9.8) followed by incubation of the plates at room temperature for 30 min. The reaction was read in a Titertek Multiskan (Flow Laboratories) at 405 nm. Titres were calculated as the serum dilution yielding a specific extinction (HSV antigen minus mock-infected cell antigen) of 0.2 by a linear regression method (Knoblich, 1984) .
Inactivation of virus. Octylpyranoside: HSV-2-infected (D-316) secondary mouse embryo fibroblasts were washed twice with Hanks' solution and the Glasgow modification of Eagle's medium (GMEM) afterwards. The virus-containing supernatant was made 2~ with respect to octylpyranoside and incubated at 37 °C for 18 h. Afterwards the detergent was removed by extensive dialysis against GMEM. The preparation did not contain infectious particles as determined by plaque tests. Heat inactivation: infectious virus was heat-inactivated for 30 min at 70 °C. No infectious virus could be detected after heating.
Drugs and chemicals. Amorphous silica (particle size 0-5 to 10 gm), octylpyranoside and Escherichia coli lipopolysaccharide (LPS) were purchased from Sigma. Bestatin was kindly provided by W. E. G. Mfiller, Institute of Physiological Chemistry, University of Mainz, F.R.G. Polyinosinic polycytidylic acid complexed via L-lysine with CM-cellulose [poly-I :C(LC); lot 138-1] was a kind gift of Dr H. B. Levy (NIH, Bethesda, Md., U.S.A.). Cyclophosphamide was obtained from Asta Chemicals, Bielefeld, F.R.G. Dextran sulphate 500000 (DS 500) and colchicine were purchased from Serva, Heidelberg, F.R.G.
HSV vaccine. For some experiments, a formalin-inactivated HSV-1 or HSV-2 vaccine prepared from primary rabbit kidney cells infected with three different strains of HSV each was used. The virus content of the preparation was about 1.0 × 107 per 0.2 ml (HSV-1) and 3 × 106 (HSV-2) (Andonov et al., 1978) . Four-hundred gl of the vaccine solubilized in Hanks' solution was injected. One dose for immunization contained 300 gg of protein.
RESULTS

Antibody induction by different strains of HSV-1 and HSV-2
There is a great variability in the pathogenicity and biochemical properties of HSV strains. Therefore, we first performed dose-response experiments in order to compare the ability of several strains of HSV-I and HSV-2 to generate a primary antibody response in mice.
As can be seen from Fig. 1 there were considerable differences in neutralizing antibody levels generated by different strains of HSV-1 and HSV-2. The most striking phenomenon was the comparatively low immunogenicity of strains of HSV-2 compared to HSV-1. Only infection of mice with a high dose (105 p.f.u.) of HSV-2 strain HG 52 resulted in higher antibody levels. Mice did not survive when infected with strain D-316 at this dose. 
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Antibody formation after infection with HSV-1 and HSV-2 in different stra&s of mice and in rats
The experiments described above were done in NMRI mice infected intraperitoneally (i.p.) with HSV-2. It then had to be demonstrated that our results were not limited to NMRI mice but could also be observed in other mouse strains infected i.p. None of seven inbred strains of mice generated an antibody response exceeding that obtained in NMRI mice (Table 1) .
We also tested whether infection at different sites (footpad, vagina, subcutaneous tissue, muscle) or intravenously might yield a stronger antibody response. Only infection into footpads resulted in antibody titres slightly higher than marginal (data not shown). As the phenomenon of 
infected intraperitoneally with 1 x 103 p.f.u, of HSV-2 (strain D-316). a weak primary antibody response to HSV-2 could be peculiar to mice, we also examined antibody formation in rats after infection with HSV-1 and HSV-2. HSV-2-infected rats produced less neutralizing antibodies to HSV-2 compared to anti-HSV-1 antibodies in HSV-1 infections (Table 2 ). This was also true for antibodies assayed by ELISA.
Comparison of neutralizing and ELISA antibody titres after infection of mice and rats with HSV-1 or HSV-2*
In order to exclude the possibility that weak antibody formation to HSV-2 compared to HSV-I (Knoblich et al., 1983a) might be due to low amounts of viral antigen produced in these mice, we studied the content of virus in several organs of mice which were infected with HSV-2.
From * Female N MRI mice were infected i.p. with I x l03 p.f.u, of HSV-1 (Lennette)or HSV-2 (HG 52). At the times indicated, they received i.p. 70 ~tg poly-I :C(LC) diluted in 0-2 ml Hanks' solution. Twenty-one days after infection, animals were bled.
t Reciprocal values; +, difference from the control group significant at P < 0.05; ND, not determined. (Knoblich et al., 1983a) , the amount of infectious virus was generally lower. Even if mice were infected with the antibody-generating dose of 105 p.f.u, of strain HG 52 (HSV-2), the virus content in the visceral organs remained low. No virus could be detected in the thymi of these mice, unlike HSV-1 infections (Caspary et al., 1980) .
It might be argued that certain peculiarities of infection with live HSV-2 compared with HSV-1 might be responsible for the low antibody formation. We therefore tested an inactivated vaccine of HSV-2 (Andonov et al., 1978) for its antibody-producing capacity and also included silica in the test. Only very low antibody production and no enhancement by injection of silica could be observed (data not shown). This is in sharp contrast to results obtained after use of an HSV-1 vaccine (Knoblich et al., 1983b) . In order to evaluate the extent to which the antibody response is dependent upon replication of the respective virus in mice, mice were also injected with HSV preparations inactivated by treatment with octylglycoside or heat. The inactivated HSV-2 also failed to generate higher antibody levels (data not shown).
Influence of immune-modulating compounds on antibody formation against HSV-2
In mice infected with HSV-1, an increase in HSV-specific antibody levels could be achieved by administration of various immune-modulating compounds interacting with different compartments of the immune system . Therefore, whether or not a similar treatment of HSV-2-infected mice would yield a comparable augmentation of the antibody response was tested. Macrophages in the peritoneal cavity can be destroyed by silica (Allison et aL, 1966; McGeorge & Morahan, 1978; Zisman et al., 1970) . Silica treatment of H SV-1-infected mice produces a strong increase in antibody titres, if given from day 4 before up to day 12 after infection (Knoblich et al., 1983 a) . After infection with HSV-2, a significant increase of antibody levels could be detected only when silica was injected once at day 5 before, the day of infection or the day after but not later (Table 4) . The T-lymphocyte-stimulating dipeptide bestatin strongly enhances antibody to HSV-1 if injected once between day 5 and day 8 after infection ; in HSV-2-infected mice, however, bestatin had no influence on generation of antibody after infection with HSV-2 (data not shown). After infection with HSV, high-dose cyclophosphamide treatment of mice increases the severity of infections and reduces antibody formation (Worthington et al., 1980) . Administration of cyclophosphamide at low doses diminishes T-suppressor lymphocyte functions (R611inghoff et al., 1977) . In contrast to earlier results obtained with HSV-1 (Knoblich et at., 1984) , injection of cyclophosphamide into mice infected with HSV-2 did not affect antibody levels when given up to 5 days after infection (data not shown). Several methods have been developed to replace the function of helper T-cells in initiation of an antibody response. Some of the compounds used for this purpose were tested with respect to enhancement of the HSV-2-specific humoral immune response. Neither the injection of DS 500, LPS nor colchicine affected the poor immunogenicity of HSV-2 after infection of mice with this serotype (data not shown). Treatment of HSV-l-infected mice with poly-I :C(LC) causes an increase in antibody levels . This compound was also tested in HSV-2-infected mice. Table 5 shows that application of poly-I:C(LC) 3 and 5 days after infection of mice with HSV-2 (HG 52) produced a low augmentation of neutralizing antibody titres. With HSV-t (Lennette), we observed a marked increase of antibody levels when poly-I :C(LC) was given at these times.
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Influence of the primary infecting HSV serotype on the effect of booster infections by either serotype
Finally, we tested the degree to which mice infected with either HSV-1 or HSV-2 could be restimulated by a booster infection with either serotype ( Table 6 ).
Mice that had been primarily infected with HSV-1 were boosted as efficiently by a secondary infection with HSV-1 as with HSV-2. Only barely detectable antibody titres were observed in mice after a primary or two subsequent infections with HSV-2. Mice infected with HSV-2 and boosted with HSV-1 had lower titres of neutralizing antibody than mice after a single infection with HSV-1 alone. This observation could also be made after primary infections with strains D-316, Lux syn 292/74 and BRY. Thus, this kind of suppression appears to be a property of many strains of HSV-2. Table 7 shows the cross-neutralizing capacity of sera from either HSV-1-or HSV-2-infected mice. HSV-1 sera had an antibody titre slightly lower if tested against HSV-2 than against HSV-1. HSV-2 sera yielded very low values whether tested against HSV-1 or HSV-2.
DISCUSSION
The present study describes several aspects of antibody formation to HSV-1 and HSV-2 in mice. Infections of mice with HSV-1 always resulted in higher antibody levels than infections with HSV-2. This finding could be confirmed in several inbred and outbred strains of mice and in rats. Weak humoral immune responses to HSV-2 were detected reproducibly by the ELISA technique and by an assay for neutralizing antibodies. Generation of low amounts of antibodies after injection into mice have been reported both for infectious HSV-2 (Morahan et aL, 1977) and for an HSV-2 vaccine (Hilleman, 1979) .
The comparatively low antibody response generated by HSV-2 might be explained in part by low multiplication rates of HSV-2 (compared to HSV-I) in mice. Low rates of replication of HSV-2 in macrophages are well documented (G6ertz et al., 1984) . Also, the interaction of HSV-1 and HSV-2 with T-lymphocytes varies widely (Knoblich et al., 1983b) . With some strains of HSV-2, a 100-or 1000-fold increase of the infecting dose did not result in production of higher antibody levels. On the other hand, infections with 105 p.f.u, of HSV-2 (HG 52) resulted in a strong antibody response without significant titres of infectious virus being detectable in various tissues. Thus, in contrast to HSV-1 (Knoblich et al., 1983a) , there is no positive correlation between virus inoculum and the antibody response in HSV-2 infections.
Regulation of the immune response involves many components, and hence we examined whether a particular one of these components might be affected by HSV-2. Macrophages participate in the initiation of specific immune responses, but are also known to release factors inhibitory for cell proliferation, among them prostaglandins (Humes et al., 1977; Metzger et al., 1980) . In HSV-1 infections, antibody levels can be augmented by a single i.p. dose of the macrophage-destroying compound silica between day 4 before and day 12 after infection (Knoblich et al., 1983a) , but during infections with HSV-2, the modulating effect of silica was only weak. It was restricted to day 5 before, the day of infection and the day after. These results indicate that the low level of antibodies produced during infections with HSV-2 may in part depend on a macrophage-dependent 'suppressor' mechanism.
Bestatin, a T-lymphocyte mitogen derived from a streptomycete, which presumably acts on helper T-cells (Ishizuka & Umezawa, 1983) and by binding to T-cells and macrophages (Miiller et al., 1982) has been successfully used to amplify antibody formation against HSV-1 ( Knoblich et al., 1984) . In HSV-2 infection however, the mechanisms involved in the regulation of antibody formation appeared to be unresponsive to bestatin. Thus, HSV-2 might impair the function ofThelper cells. Therefore, several drugs able to replace T-helper function and directly initiating antibody responses were tested. DS 500 and LPS act on B-cells (Diamantstein et al., 1973 ; colchicine directly affects antibody-forming cells and also reduces suppressor cell activities ; cyclophosphamide at low doses reduces the effects ofT-suppressor cells (R611inghoff et al., 1977) and has been shown to augment antibody titres in HSV-1 infections . However, none of these drugs was able to enhance antibody levels after infections with HSV-2. Synthesis and secretion of interferons, known to be potent immunomodulators (Johnson, 1981) , can be induced by poly-I : C (Champney et al., 1979; Martinez et al., 1980; Stebbing et al., 1980) . Compared to infection with HSV-1 where treatment with poly-I : C(LC) results in an enhancement of antibody levels , only slight increases of antibody titres could be seen in HSV-2 infection. This effect may be explained v. KAMPE AND OTHERS by immuno-enhancing activities of interferon (Johnson, 1981 ; Friedman & Vogel, 1983) , or by direct stimulation of B-cells by this compound (Riihl et al., 1974) .
As shown above, high doses of HSV-2 (HG 52) were able to stimulate a marked antibody response despite the general lack of immunogenicity of the structural components of HSV-2 strains. Apparently, the weak antibody response could be attributed to some kind of immunosuppression. Suppressive effects of HSV have been observed in delayed-type hypersensitivity (Nash & Gell, 1980) and seem to be involved in induction of recrudescence (Iwasaka et al., 1983) . Pelton et al. (1980) reported the inhibition of antibody formation in vitro against diphtheria toxin by HSV-1 and concluded that HSV-1 kills helper T-cells. Crossinfections with both HSV-1 and HSV-2 were performed in vivo to investigate whether HSV-2 might exert suppression of the antibody response. Once mice had been primed with HSV-1, boosting was effective both with HSV-1 and HSV-2, but if priming was done by infection with HSV-2, the antibody response following subsequent infection with HSV-1 was much lower than that following a single infection with HSV-1. Thus, once an immune response to HSV-I has been initiated, type-common determinants of HSV-2 antigens induce a strong secondary response. It might be excluded, therefore, that low antibody titres following HSV-2 infections are the result of destruction of B-lymphocytes by HSV-2, which is known to multiply in dividing B-cells (Kirchner et al., 1976) . The failure of HSV-2 to induce marked antibody levels has to be explained by serotype-specific immunosuppression influencing antibody formation both against the homologous and the heterologous serotype. The nature of this suppression is under further investigation.
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